Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Skin
14:32

Xth Eurasian Hematology-Oncology Congress

2019 Update on Adjuvant Treatment of Melanoma: CPIs and BRAF MEK Are More Effective and Tolerated, Interferon Alfa Not Recommended for Cutaneous Disease, & What Therapy in BRAF Mutant Disease

FEATURING Zeynep Turna
  • 32 views
  • December 4, 2019
06:35

Xth Eurasian Hematology-Oncology Congress

2019 Update on Neoadjuvant Treatment of Melanoma: Immunotherapy Provides Better Outcome Than Targeted Therapy in Partial Response Patients and Better RFS

FEATURING Zeynep Turna
  • 21 views
  • December 4, 2019
21:19

Xth Eurasian Hematology-Oncology Congress

Markers for Immune Checkpoint Inhibitor Resistance in Skin Cancer: Mechanisms, WNT/Beta Catenin Signalling, JAK1/JAK2, Myeloid Derived Suppressor Cells, Alternative CPIs, and TMB

FEATURING Selcuk Seber
  • 252 views
  • December 4, 2019
  • 1
05:25

Xth Eurasian Hematology-Oncology Congress

The Evolution of Metastatic Melanoma Treatment: Does PD-L1 Status Alone Suggests IO Treatment Option?

FEATURING Dilek Erdem
  • 29 views
  • December 4, 2019
15:44

Xth Eurasian Hematology-Oncology Congress

Metastatic BRAF+ Melanoma Treatment: Do We Sequence or Combine IO w/Targeted Therapy, What's the "Right" Frontline Therapy, TMB, Wild Type Disease, Potential Biomarker for Long-Term Benefit

FEATURING Dilek Erdem
  • 44 views
  • December 4, 2019